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What is known about this topic? 
• Several new promising treatments for patients with metastatic melanoma that harbour BRAF 
V600E or V600K mutations have recently become available 
• Trametinib is not yet available in Switzerland, but approval is expected in 2015 
• These new treatments are very expensive 
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What does this study add? 
• Although clinically promising, at current US trametinib prices, trametinib plus dabrafenib will 
not be cost effective compared to vemurafenib in the Swiss setting 
• Only a reduction in the price of the combination therapy would make this therapy cost 
effective 
 
Abstract 
Background and Objective: The treatment of patients with metastatic melanomas that harbour BRAF 
V600E or V600K mutations with trametinib plus dabrafenib appears to be superior to treatment with 
vemurafenib alone. This treatment regimen is likely to become available in Switzerland in the near 
future. However, its cost-effectiveness is unknown. 
Methods: A Markov cohort simulation was conducted to model the clinical course of typical patients 
with metastatic melanoma. Information on response rates, clinical condition, and follow-up 
treatments were derived and transition probabilities estimated based on the results of a clinical trial 
that compared treatment with trametinib plus dabrafenib versus vemurafenib alone. 
Results: Treatment with trametinib plus dabrafenib was estimated to cost an additional CHF199,647 
on average and yield a gain of 0.52 quality-adjusted life years (QALYs), resulting in an incremental 
cost-effectiveness ratio of CHF385,603/QALY. Probabilistic sensitivity analyses showed that a 
willingness to pay threshold of CHF100,000/QALY would not be reached at trametinib’s current 
United States price. 
Conclusion: The introduction of trametinib in Switzerland at US market prices for the treatment of 
metastatic BRAF V600-positive melanoma with trametinib plus dabrafenib is unlikely to be cost 
effective compared to vemurafenib monotherapy. A reduction in the total price of the combination 
therapy is required to achieve an acceptable cost-effectiveness ratio for this clinically promising 
treatment. 
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Introduction 
At 25.8 per 100,000 population per year, melanoma incidence in Switzerland is the highest of 40 
European countries, and Switzerland is ranked sixth in Europe in terms of melanoma mortality (3.5 
per 100,000) 1. Approximately 50% of melanomas harbour activating BRAF mutations 2, and drugs 
that inhibit the downstream mitogen-activated protein kinase (MAPK) cascade in melanoma cells 
have been developed over the last few years. These targeted therapies have had substantial clinical 
impact in patients with BRAF mutated melanoma. The MAPK-targeting therapies include several 
selective tyrosine kinase inhibitors such as vemurafenib (VEM), dabrafenib (DAB), and the MEK1 
and/or MEK2 enzyme inhibitors trametinib (TRAM) 2-8, binimetinib9 or cobimetinib10. These drugs 
have all been shown to improve clinical response rates (alone or in combination) , progression-free 
survival (PFS) and overall survival (OS)11, 12 in patients with metastatic BRAF-mutated melanomas 
when compared to drugs such as dacarbazine4, and other chemotherapies 13. The reported median 
progression free survival times for these new drugs (in mono-therapy) are quite similar. All of these 
targeted therapies are now available in Switzerland except for trametinib14. However, these new 
drugs are extremely expensive compared to standard chemotherapies.  
In a recent randomised controlled trial, trametinib plus dabrafenib (TRAM+DAB) combination 
therapy was compared to VEM monotherapy 12. In previously untreated patients with metastatic 
melanomas harbouring BRAF V600E or V600K mutations, TRAM+DAB (median PFS 11.4 months, 
median OS not reached) significantly improved progression free and overall survival compared to 
VEM monotherapy (PFS 7.3 months, OS 17.2 month). Overall toxicity was not increased. 
A cost-effectiveness analysis from the Canadian healthcare perspective showed that treatment with 
TRAM alone vs. dacarbazine may not be cost effective from the societal perspective but may be cost-
effective compared to VEM 15. In addition, DAB has been shown not to be cost-effective compared to 
dacarbazine in the Canadian healthcare system 16. Curl et al 17 showed that VEM itself would not be 
cost effective with its current price compared to dacarbazine in the US. VEM in combination with 
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ipilimumab compared to dacarbazine was more cost-effective but the incremental cost effectiveness 
ratio (ICER) was still higher than most desirable willingness to pay thresholds. 
DAB and VEM have both been approved for use in Switzerland, and their costs are known 
(www.swissmedic.ch, http://compendium.ch). VEM can be regarded as one of the standard therapies 
for the given indication in Switzerland. However, reimbursement is conditional upon pre-approval by 
the responsible health insurance company 18.  TRAM so far is not yet available in Switzerland. If TRAM 
is approved in Switzerland (expected in 2015) for BRAF-positive metastatic melanoma patients and 
used in clinical practice in combination with DAB rather than VEM, it is important to determine its 
cost-effectiveness prior to approval to help negotiate optimal prices for healthcare acquisition. 
Therefore, we used the clinical outcomes reported by Robert et al. 12 to evaluate the cost 
effectiveness of the TRAM+DAM strategy compared to VEM with respect to the Swiss healthcare 
system. The USA price for TRAM was used for the base case evaluation, and different pricing 
scenarios for the combination therapy were investigated for the assessment of possible willingness-
to-pay (WTP) thresholds. 
 
Methods 
A Markov model was constructed to assess the cost-effectiveness of treatment strategies for patients 
with metastatic BRAF V600-mutated melanoma. Combination therapy with dabrafenib (150 mg twice 
daily) and trametinib (2 mg once daily) was compared to vemurafenib (960 mg twice daily) orally as 
first-line therapy. The clinical model was based on the study by Robert et al. 12. Drug therapies, major 
adverse events, and second-line treatments during progression were considered as direct medical 
costs from the perspective of the Swiss healthcare system, and a lifelong time horizon was adopted 
to capture related costs and outcomes. Drug prices were based on Swiss prices and tariff lists (except 
for TRAM, which was based on USA prices and converted to Swiss Francs according to the average 
exchange rate in January 2015). The health state utilities used in the model were obtained from the 
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literature 15, 19. The effect of discounting for cost and effects on the ICER for a discount rate of 3 and 
6% per year after the first year was assessed. 
Metastatic melanoma patients eligible for the original multicentre, open-label phase 3 study had 
proven BRAF V600E or V600K mutations. In total, 704 patients were randomised to receive either 
TRAM (2mg/day)+DAB (150mg/twice daily) or VEM (960mg/twice daily) orally until progression; 
some patients continued on the study medication for some time after disease progression 12. Of the 
observed adverse events, 48% (TRAB+DAB arm) and 57% (VEM arm) were grade 3. According to a 
personal communication with Prof. R. P. Braun, University Hospital Zürich, almost none of the 
observed events reported would have required any specific cost-inducing treatments except for the 
treatment of cutaneous squamous cell carcinoma, which was observed in VEM-treated patients more 
often (grade 3, 17%) than TRAM+DAB-treated patients (grade 3, 1%). 
In our analysis, the primary endpoint was the incremental cost-effectiveness ratio (ICER) expressed 
as cost per quality-adjusted life year (QALY) gained of TRAM+DAB compared to VEM in patients with 
metastatic BRAF-mutated melanoma. ICERs were compared to possible WTP thresholds of 
CHF50,000-CHF100,000 per QALY gained. 
In addition, one-way, two-way, and probabilistic sensitivity analyses were performed to test the 
robustness of the results. Sensitivity analyses for the given TRAM+DAB drug prices and one 
alternative price scenario were carried out to evaluate the price at which TRAM combined with DAB 
may be cost effective. Furthermore, the budget impact on the Swiss healthcare system was 
estimated. The model was built and all analyses were performed in TreeAge Pro 2015®. 
 
Model structure 
The Markov model comprised three mutually exclusive health states as shown in Figure 1: 
stable/responsive (progression-free) disease, disease progression, and death. A cycle length of one 
month was chosen to match the outcomes and medication schemes of the original study. All patients 
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started with stable progression-free disease, where they either remained or transitioned to 
progressive disease. Once in the progressive stage, patients could remain in this stage or transition to 
death. 
Clinical effectiveness and quality of life 
Effectiveness data were inferred from the PFS and overall survival outcomes reported in the original 
publication. Hazards were assumed to be constant over time, and the median time spent in each 
state was used to estimate hazard rates for the VEM strategy based on the formula: hazard rate=-
ln(0.5)/median time in state. Thereafter, hazard rates were converted into Markov state transition 
probabilities. To model time to progression and overall survival in the TRAM+DAB strategy, hazard 
rates in the VEM strategy were multiplied by the applicable hazard ratios (HR). 
The median time from progression to death in the VEM strategy was estimated to fit the reported 
median overall survival time in the VEM strategy because this information was not provided in the 
original publication. Thereafter the HR for death was used to estimate an approximate median 
overall survival time for the TRAM+DAB strategy, which was not available at the time of publication. 
Quality-adjusted progression-free time and time in progression were calculated according to 
published utilities: VEM calculations were based on a population-based survey using the standard 
gamble method 17, 19, and for TRAM+DAB (using utilities for TRAM as reported by Amdahl et al.15 ) 
calculations were EQ-5D based (see http://www.euroqol.org) 15, 20.  
All values for the base case input parameters are listed in table 2 (mean values). 
 
Use of medical resources and unit costs 
Only drug use and adverse event information were provided in the publication by Robert et al. 12; 
there were no data on other medical resource use such as hospitalisations or other supportive care. 
Therefore, the costs considered in the model were only based on study and follow-up drug costs (see 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 1 for unit prices and treatment schemes) and estimated costs for the treatment of adverse 
events. A price of CHF165/mg of TRAM was assumed, and the prices for the other drugs were set 
according to Swiss tariffs. No costs for in- and/or out-patient supportive care were included (see 
details in the discussion).  
No costs were attached to specific adverse events; instead, an overall cost distribution from a 
minimum of CHF0 (for adverse events not requiring treatment) to a maximum of CHF 1,400 per 
adverse event was employed to cover possible treatment costs in both strategies. Costs for the 
treatment of cutaneous squamous cell carcinoma were estimated to be ±CHF1,000 and were 
included in the distribution.  
Follow-up treatments were implemented in the model as observed in the original study 
(Supplementary Material 12, Table 1). Swiss public healthcare prices were used for all drugs except 
TRAM (USA price, no Swiss price available). The duration of follow-up treatments with study 
medication was modelled according to the original study. Three follow-up cycles of drugs other than 
the study medications were assumed, as per common practice. 
Sensitivity analyses and price scenarios 
The influence of uncertainty on key model parameters was assessed by a series of one-way 
sensitivity analyses and a probabilistic sensitivity analysis. In the one-way sensitivity analyses, all 
parameters subject to uncertainty were varied across plausible ranges as shown in Table 2. 
Probabilistic sensitivity analysis (a second-order Monte Carlo simulation) was based on the 
corresponding distributions of the parameters (see Table 2). 
A two-way sensitivity analysis, in which the price of TRAM and DAB was varied simultaneously, was 
performed in order to calculate alternative ICERs for comparison with possible WTP thresholds of 
CHF50,000 and CHF100,000 per QALY. Although there is no official cost per QALY gained threshold in 
Switzerland, WTP thresholds including a WTP threshold of CHF 80,000 per QALY were used in line 
with a recently published analysis for the Swiss setting 21. In addition, two separate probabilistic 
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sensitivity analyses were performed: one with base case prices for TRAM+DAB and one with both 
drugs half the price of the base case situation. These analyses provided information about the 
probability of the TRAB+DAB treatment being cost effective compared to the given WTP thresholds. 
 
Model validation 
The model was adjusted to match the progression-free and overall survival data (only for the VEM 
treatment strategy) in the original Robert et al. 12 study. Trackers for progression-free survival and 
overall survival were included to assess for correct data fit. All outputs were reviewed for plausibility. 
Key input parameters were subjected to extreme variation to assess the accuracy of the model.  
 
Results 
The clinical outcomes of the original study were reproduced in the model as follows: median PFS for 
TRAM+DAB and VEM in the Robert et al. 12 study were 11.4 and 7.3 months, respectively. The model-
based median PFS was 11.3 months (TRAM+DAB) and 7.4 months (VEM), thereby satisfactorily 
matching the results of the original study. The model-based median overall survival for the VEM arm 
also reasonably fitted the original data (17.8 in the model versus 17.2 months in the original data). 
With respect to the TRAM+DAB strategy, the median overall survival from the model was 25.9 
months. This result could not be directly confirmed using the original data (no median overall survival 
reached at the time point of data extraction for publication 12) but seemed plausible from 
extrapolation of the original data. 
The base case model indicated that TRAM+DAB (mean cost CHF311,421; mean effect 1.54 QALYs) 
compared to VEM (mean cost CHF111,773; mean effect 1.02 QALYs) in patients with BRAF-positive 
metastatic melanoma leads to a gain of 0.52 QALYs per patient at an additional cost of CHF199,647. 
This resulted in an ICER of CHF385,603 per QALY gained (see Table 3). Discounting by 3 or 6% per 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
year (starting after the first year) for costs and effects marginally increased the ICER as shown in 
Table 3. 
Univariate sensitivity analyses showed that varying the utility (quality of life) for the time in 
progression for the TRAM+DAB strategy had the highest impact on the ICER, followed by the HR for 
death. Further parameters that had a substantial impact were utility PFS for the TRAM+DAB strategy, 
hazard ration PFS,  time to PFS (VEM), time from PFS to death (VEM), and the utilities for the 
corresponding VEM stages, as shown in Figure 2. None of the tested variations in key parameters 
resulted in an ICER below a WTP threshold of CHF100,000/QALY. In a separate analysis, we applied 
the utility for the progressive disease state observed in VEM-treated patients to both strategies. The 
ICER increased to 508’532CHF/QALY. Using the utility for the progressive disease state applied in 
TRAM+DAB patients for both strategies resulted in a similar ICER of 502’397CHF per QALY gained. In 
both cases the ICER increased because the differences in effects decreased.  
Two-way sensitivity analysis (Figure 3), in which the prices of TRAM and DAB were varied 
simultaneously, showed that TRAM would need to be priced at almost zero with the current price of 
DAB in order to achieve an ICER of no less than CHF100,000/QALY. Even if the price of DAB could be 
reduced by at least 50%, the price of TRAM would need to be far below the current US price in order 
to achieve ICERs that might be regarded as acceptable. 
Probabilistic sensitivity analyses confirmed these results (Figure 4). Based on current prices, the 
probability that TRAM+DAB versus VEM would be cost effective was zero. Reducing both the price of 
TRAM and DAB by 50% resulted in a 3% probability that the TRAM+DAB treatment compared to VEM 
would be cost-effective with respect to a WTP threshold of CHF50,000/QALY and 73% with respect to 
a WTP threshold of CHF100,000/QALY. A combined price for TRAM+DAB of about CHF 5’335 per 
month would match a WTP of CHF 50’000 per QALY gained; a price of about CHF 7’590 would match 
a WTP of CHF 100’000 per QALY. We next estimated the impact of the introduction of TRAM+DAB 
combination therapy on the Swiss healthcare system budget. Based on 2012 data, mortality from 
melanoma in Switzerland was 3.65/100,000 1, i.e., approximately 300 melanoma deaths per year in a 
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population of 8,039,100 (2012, www.bfs.admin.ch). If 40% of the patients’ cancers have a suitable 
BRAF mutation and assuming all are treated with TRAM+DAB, this would result in a total average 
spend of 37 million Swiss francs (drug costs only), almost 24 million more than treatment with VEM. 
 
Discussion 
The global incidence of melanoma is rapidly increasing in the white population 22. The development 
of diagnostic tests that detect specific mutations to direct targeted therapy has resulted in several 
new treatment options with promising clinical outcomes 4-8, 12, 13. However, the costs of these new 
treatments are high, and several health economic analyses have concluded that they might not be 
cost effective 15-17. In our study, we analysed the cost-effectiveness of trametinib (TRAM) plus 
dabrafenib (DAB) combination therapy versus vemurafenib (VEM) for patients with BRAF V600-
mutated metastatic melanoma. Follow up treatments were modelled as observed in the clinical trial 
performed by Robert et al. 12. VEM is frequently used  in Switzerland despite its high costs, and lack 
of cost-effectiveness reported for the US17. TRAM is expected to be approved for use in Switzerland 
in 2015 (personal communication Prof. Dummer), but the drug price for the Swiss market has yet to 
be established.  
Using clinical data from the study performed by Robert et al. 12, treatment with TRAM+DAB 
compared to VEM resulted in a predicted ICER of CHF385,603 per QALY gained and discounting costs 
and effects for 3 or 6%  slightly increased the ICER. This is in line with other cost-effectiveness 
analyses for TRAM 15 and other treatment strategies for BRAF-mutated metastatic melanoma 17.  This 
ICER is far higher than the WTP thresholds proposed - but not generally accepted - for Switzerland 
(CHF80,000/QALY 21) and those used in other European countries (between 30,000 and 50,000 
€/QALY 23-25). Since the Swiss market price for TRAM is still unknown, we evaluated possible price 
scenarios for TRAM that would meet acceptable WTP thresholds: we calculated that the price of 
TRAM would need to be almost zero in order to make this combination therapy cost effective, which 
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is, quite clearly, unrealistic. The probability that combination therapy might become cost effective 
only increases if the total “combination therapy” price can be reduced (cost reduction for DAB and a 
far lower price for TRAM than currently set in the USA). Moreover, since the cost-effectiveness of 
vemurafenib compared to other treatments is not given 17, the probability that TRAM+DAB 
combination therapy is cost effective compared to these (older) therapies is highly unlikely. Although 
there is no official WTP threshold for Switzerland, these analyses show that introducing TRAM to the 
Swiss market for metastatic melanoma may be of high clinical benefit but is highly unlikely to be cost-
effective. 
The impact of an additional 24 million Swiss Francs spend (compared to treatment with VEM) would 
increase the cancer treatment budget in Switzerland by 0.5% (the total treatment costs for cancer 
patients in Switzerland in 2011 was 4,005 million Swiss Francs), or 5% when only drug costs are taken 
into account (www.interpharma.ch). This would only have a marginal impact compared to overall 
treatment costs for cancer patients in Switzerland, mostly due to a low number of eligible patients 
per year.  
Our analysis has several limitations. First of all, at the time point of analysis as reported in the 
underlying trial by Robert et al. 12 medium OS in the TRAM+DAB arm was not yet reached. Possibly 
durable responses in some patients would not have been visible yet. The occurrence of such long-
term responses could decrease the ICER, but there are no data so far to affirm this possibility. . Then 
we could only examine the cost data for drug treatments since no clinical care data (hospitalisations, 
supportive or palliative care) were available. However, it can be assumed that clinical care is similar 
for all patients; only the duration of care due to different overall survival times between treatment 
strategies might have produced a cost difference. It is unclear how strong these cost effects might be 
on the ICER, but given the longer overall survival time for patients in the TRAM+DAB strategy, these 
patients could reasonably be assumed to incur higher costs and further disadvantage this treatment 
option. Furthermore, quality of life data were not recorded in the original study, and we had to rely 
on health state utility information from other studies for modelling, using different methodologies 15, 
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19. The utilities used for the TRAM+DAB strategy were those used for patients treated with TRAM 
monotherapy, and it is unclear if the combination therapy might have resulted in other utilities. As 
shown in the univariate sensitivity analyses, variation of utility parameters had a strong effect on the 
ICER and, depending on the shift in estimated utilities for the combination therapy, this may affect 
the ICER. Moreover, the model did not include a separate state representing “response to therapy” 
with a possibly reduced disease burden and thus higher utility than other persons in the progression 
free state. In addition, we assumed that the cost for treating the observed adverse events would not 
be very high (personal communication, R. Braun). This contradicts the results from an other study, 
which concluded that the incremental costs associated with many melanoma treatment-related 
adverse events are substantial 26. However, this previous study included patients treated with 
paclitaxel, vemurafenib, ipilimumab, dacarbazine, temozolomide, high-dose interleukin 2, interferon 
α, dabrafenib, or trametinib, each of which have very different safety implications. These results are 
therefore not directly comparable and underpinned our decision to not add additional cost 
uncertainty into the model by costing separate adverse events without proof of validity. Finally, 
patients in usual clinical practice may not be as fit as the study population and might be less likely to 
benefit from these antineoplastic treatments, further impairing the cost-effectiveness of TRAM+DAB.  
 
Conclusion 
Here, we show that the introduction of trametinib, priced according to its current US market cost, to 
treat Swiss metastatic BRAF V600-positive melanoma patients with a combination therapy of 
trametinib and dabrafenib is unlikely to be cost effective compared to vemurafenib monotherapy. 
The total price for the combination therapy needs to be reduced by negotiating lower prices for both 
trametinib and dabrafenib to achieve an acceptable cost-effectiveness ratio for this clinically 
promising treatment. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Acknowledgements 
 
References 
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. 
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 
2013;49(6):1374-403. 
2. Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF 
V600 mutation in melanoma. Journal of translational medicine. 2012;10:85. 
3. Dossett LA, Kudchadkar RR, Zager JS. BRAF and MEK inhibition in melanoma. Expert opinion 
on drug safety. 2015:1-12. 
4. Menzies AM, Long GV. Dabrafenib and trametinib, alone and in combination for BRAF-
mutant metastatic melanoma. Clin Cancer Res. 2014;20(8):2035-43. 
5. Awad MM, Sullivan RJ. Dabrafenib in combination with trametinib for the treatment of 
metastatic melanoma. Expert review of clinical pharmacology. 2015;8(1):25-33. 
6. Chung C, Reilly S. Trametinib: a novel signal transduction inhibitor for the treatment of 
metastatic cutaneous melanoma. Am J Health Syst Pharm. 2015;72(2):101-10. 
7. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in 
BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. 
Lancet. 2012;380(9839):358-65. 
8. Beale S, Dickson R, Bagust A, Blundell M, Dundar Y, Boland A, et al. Vemurafenib for the 
treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a 
NICE single technology appraisal. Pharmacoeconomics. 2013;31(12):1121-9. 
9. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, et al. 
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-
randomised, open-label phase 2 study. Lancet Oncol. 2013;14(3):249-56. 
10. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib 
and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-76. 
11. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and 
trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-
blind, phase 3 randomised controlled trial. Lancet. 2015. 
12. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. 
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 
2015;372(1):30-9. 
13. Aris M, Barrio MM. Combining immunotherapy with oncogene-targeted therapy: a new road 
for melanoma treatment. Frontiers in immunology. 2015;6:46. 
14. Dummer R, Guggenheim M, Arnold AW, Braun R, von Moos R, Project Group Melanoma of 
the Swiss Group for Clinical Cancer R. Updated Swiss guidelines for the treatment and follow-up of 
cutaneous melanoma. Swiss Med Wkly. 2011;141:w13320. 
15. Amdahl J, Wang A, Thabane M, Amonkar M, Delea TE. Cost Effectiveness of Trametinib as 
First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian 
Societal Perspective. Value in Health.17(3):A83. 
16. Delea TE, Amdahl J, Wang A, Amonkar MM, Thabane M. Cost Effectiveness of Dabrafenib as a 
First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic 
Melanoma in Canada. Pharmacoeconomics. 2014. 
17. Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG. Cost-effectiveness of treatment strategies 
for BRAF-mutated metastatic melanoma. PLoS One. 2014;9(9):e107255. 
18. Zelboraf (Vemurafenib) http://bag.e-
mediat.net/SL2007.Web.External/ShowPreparations.aspx [Internet]. 2015. 
19. Beusterien KM, Szabo SM, Kotapati S, Mukherjee J, Hoos A, Hersey P, et al. Societal 
preference values for advanced melanoma health states in the United Kingdom and Australia. Br J 
Cancer. 2009;101(3):387-9. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
20. Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Demidov LV, Rutkowski P, et al. 
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or 
metastatic melanoma: quality-of-life analyses of the METRIC study. Ann Oncol. 2014;25(3):700-6. 
21. Brandle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WJ. Cost-effectiveness of 
pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss 
setting. Swiss Med Wkly. 2009;139(11-12):173-84. 
22. Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Advances in experimental 
medicine and biology. 2014;810:120-40. 
23. Guide to the methods of technology appraisal. Reference N1618, www.nice.org.uk. National 
Institute for Clinical Excellence. 2008. 
24. García-Altés A. Catalan Agency for Health Technology Assessment and Research (CAHTA). 
Newsletter. 2006(38). 
25. Iannazzo S, Zaniolo O, Pradelli L. Economic evaluation of treatment with orlistat in Italian 
obese patients. Curr Med Res Opin. 2008;24(1):63-74. 
26. Arondekar B, Curkendall S, Monberg M, Mirakhur B, Oglesby AK, Lenhart GM, et al. Economic 
burden associated with adverse events in patients with metastatic melanoma. Journal of managed 
care & specialty pharmacy. 2015;21(2):158-64. 
 
Figure legends 
 
Figure 1. Model structure. 
Figure 2. One-way sensitivity analysis for the 12 input parameters with the largest effect on the ICER. 
Legend: Based on 2.5% and 97.5% percentiles as shown in Table 2. Results shown are for 0% 
discounting, DAB=dabrafenib, FU=follow up, HR=hazard ratio, PFS=progression free survival, 
TRAM=trametinib, VEM= vemurafenib  
Figure 3. Two-way sensitivity analysis for the effect of the costs of trametinib and dabrafenib on the 
ICER. 
Legend: Results shown are for 0% discounting 
Figure 4. Probabilistic sensitivity analysis for the base case trametinib and dabrafenib prices and for a 
50% reduction in price.  
Legend: For a price reduction of trametinib and dabrafenib of 50%: willingness to pay = 50,000, 
probability cost effective = 3%; willingness to pay = 100,000, probability cost effective = 73%. Results 
shown are for 0% discounting 
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Tables 
Table 1. Unit prices and treatment schedules for cost input parameters 
 
Treatment Unit price Dose  Schedule Source 
Dabrafenib 1.15 CHF/mg 300mg daily http://compendium.ch/search/all/dabrafenib/startwith/de 
Trametinib 165 CHF/mg 2mg daily price based on US$ see http://GoodRx.com 
Vemurafenib 0.2 CHF/mg 960mg twice daily http://compendium.ch/search/all/vemurafenib/startwith/de 
Ipilimumab* 98 CHF/mg 3mg/kg° once in 3 weeks 
http://www.compendium.ch/search/all/Ipilimumab/star
twith/de 
Dacarbazine* 0.61 CHF/mg 850mg/m2# 
once in 3 
weeks 
http://www.compendium.ch/search/full/dacin/contains/
de 
Intravenous 
application 375 CHF/application http://www.tarmedsuisse.ch/ 
Other FU Therapies CHF 141-9971/cycle http://compendium.ch/ 
Costs for adverse 
events 
CHF 0-1400/adverse 
event    
* = intravenous application, °  basis = 60kg, # basis = 60kg / 174 cm 
 
 
 
 
Table 2. Distribution type and input values for the sensitivity analyses 
 
Treatment 
arm  Type Variable 
Distribution type 
used in probabilistic 
sensitivity analysis 
Mean° Median° 
2.5th 
perc
entil
e° 
97.5th 
percen
tile° 
 
Costs 
Costs for adverse events Gamma1) 93 41 0.08 562 
Costs for other FU treatments per 
cycle From List* 5098 5019 
161(
min) 
9918(m
ax) 
Outcome12 
Hazard ratio death Lognormal 2) 0.69 0.69 0.55 0.89 
Hazard ratio progression free 
survival Lognormal
2) 0.56 0.56 0.44 0.69 
DAB + 
TRAM 
Outcome12 % adverse events grade 3 Beta 4) 48% 48% 43% 53% 
Treatment12 
% patients continuing study 
treatment in FU  Beta 
4) 23% 23% 20% 26% 
% patients with dose reduction 
DAB+TRAM Beta 
4) 33% 33% 28% 38% 
% patients with dacarbazine in FU Beta 4) 3% 3% 2% 5% 
% patients with ipilimumab in FU Beta 4) 12% 12% 9% 15% 
% patients with other treatments 
in FU Beta 
4) 4% 4% 2% 7% 
% patients with VEM in FU Beta 4) 5% 5% 3% 8% 
Duration of study medication 
(month) in FU  Gamma
2) 2.47 1.56 0.04 9.14 
Utility15 
Utility progression free survival  Beta 3) 0.78 0.78 0.73 0.83 
Utility progression Beta 0.72 0.72 0.56 0.87 
VEM Outcome12 
% adverse events grade 3 Beta 3) 57% 57% 52% 62% 
Time to progression in months  Gamma2) 7.34 7.30 4.37 11.04 
Time from progression to death in 
months Gamma
2) 4.63 4.54 2.61 7.03 
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Treatment12 
% patients continuing study 
treatment in FU  Beta 
4) 23% 23% 19% 28% 
% patients with dose reduction 
VEM  Beta 
4) 39% 39% 33% 44% 
% patients with DAB in FU Beta 4) 8% 8% 5% 11% 
% patients with dacarbazine in FU Beta 4) 8% 8% 6% 11% 
% patients with ipilimumab in FU Beta 4) 22% 22% 18% 27% 
% patients with other treatments 
in FU Beta 
4) 11% 11% 8% 15% 
Duration of study medication 
(months) in FU  Gamma
2) 1.45 1.03 0.06 5.54 
Utility19 
Utility progression free survival Beta 3) 0.80 0.80 0.78 0.82 
Utility progression Beta 3) 0.52 0.52 0.48 0.56 
* Swiss pharmaceutical drug information: http://compendium.ch/ , °results as calculated for 1000 samples of the distribution, 1) 
representing base case +/- 50%, 2) based on 95% confidence interval, 3) estimated from mean and standard error, 4) based on observed 
frequencies in the trial by Robert et al.12  
 
 
 
 
Table 3. Base case results 
 
Discounting Strategy Cost CHF Effect in Life Years Effect in Utilities Effect in QALYs ICER CHF/QALY
0% 
VEM 111,773 1.49 0.685 1.02 
385,603 DAB+TRAM 311,421 2.02 0.762 1.54 
Difference DAB+TRAM and 
VEM 199,647 0.53 0.078 0.52 
3% 
VEM 110,187 1.46 0.685 1 
395,204 DAB+TRAM 302,747 1.95 0.764 1.49 
Difference DAB+TRAM and 
VEM 192,560 0.49 0.079 0.49 
6% 
VEM 108,730 1.43 0.692 0.99 
404,542 DAB+TRAM 294,984 1.89 0.767 1.45 
Difference DAB+TRAM and 
VEM 186,255 0.46 0.075 0.46 
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